BR0113671A - Gem-substituted alpha v beta 3 integrin antagonists - Google Patents

Gem-substituted alpha v beta 3 integrin antagonists

Info

Publication number
BR0113671A
BR0113671A BR0113671-2A BR0113671A BR0113671A BR 0113671 A BR0113671 A BR 0113671A BR 0113671 A BR0113671 A BR 0113671A BR 0113671 A BR0113671 A BR 0113671A
Authority
BR
Brazil
Prior art keywords
gem
beta
integrin antagonists
substituted alpha
formula
Prior art date
Application number
BR0113671-2A
Other languages
Portuguese (pt)
Inventor
Ish Kumar Khanna
Yi Yu
Hwang Fun-Lu
Nizal S Chandrakumar
Renee M Huff
Mark A Russel
Mark L Boys
Lori A Schretzman
Barbara B Chen
Bipinchandra N Desai
Srinivasan Raj Nagarajan
Alan F Gasiecki
Thomas D Penning
Thomas Rogers
John Adam Wendt
Albert Khilevich
Yaping Wang
Balekudra Devadas
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0113671A publication Critical patent/BR0113671A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"ANTAGONISTAS DE INTEGRINA ALFA V BETA 3 GEM-SUBSTITUìDA". A presente invenção refere-se a uma classe de compostos representada pela Fórmula (I) ou um sal farmaceuticamente aceitável destes, composições farmacêuticas compreendendo os compostos da Fórmula (I) e métodos de seletivamente inibir ou antagonizar a integrina <244>~ v~<225>~ 3~ e/ou <244>~ v~<225>~ 5~."ALPHA V INTEGRINE BETA 3 GEM REPLACED ANTAGONISTS". The present invention relates to a class of compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the compounds of Formula (I) and methods of selectively inhibiting or antagonizing the integrin. 225> ~ 3 ~ and / or <244> ~ v ~ <225> ~ 5 ~.

BR0113671-2A 2000-08-30 2001-08-29 Gem-substituted alpha v beta 3 integrin antagonists BR0113671A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22918600P 2000-08-30 2000-08-30
PCT/US2001/026963 WO2002018340A1 (en) 2000-08-30 2001-08-29 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS

Publications (1)

Publication Number Publication Date
BR0113671A true BR0113671A (en) 2004-01-06

Family

ID=22860154

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113671-2A BR0113671A (en) 2000-08-30 2001-08-29 Gem-substituted alpha v beta 3 integrin antagonists

Country Status (16)

Country Link
EP (1) EP1313705A1 (en)
JP (1) JP2004510708A (en)
KR (1) KR20030027106A (en)
CN (1) CN1471512A (en)
AU (1) AU2001288515A1 (en)
BR (1) BR0113671A (en)
CA (1) CA2419699A1 (en)
CZ (1) CZ2003459A3 (en)
EA (1) EA200300226A1 (en)
IL (1) IL154496A0 (en)
MX (1) MXPA03001759A (en)
NO (1) NO20030925L (en)
NZ (1) NZ524159A (en)
PL (1) PL365729A1 (en)
WO (1) WO2002018340A1 (en)
ZA (1) ZA200301162B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05013637A (en) * 2003-08-13 2006-02-24 Chiron Corp Gsk-3 inhibitors and uses thereof.
EP1802618A1 (en) * 2004-10-14 2007-07-04 Pharmacia Corporation Biphenyl integrin antagonists
CN101880270B (en) * 2009-05-07 2012-10-03 上海华升生物科技有限公司 Method for preparing 1,1-cyclopropanedimethyl cyclicsulfite
PT3050878T (en) 2013-09-24 2021-12-02 Fujifilm Corp Novel nitrogen-containing compound or salt thereof, or metal complex thereof
TW202332675A (en) * 2019-10-16 2023-08-16 美商莫菲克醫療股份有限公司 Inhibiting human integrin α4β7

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
CN1209063A (en) * 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 Vitronection receptor antagonists
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
JP2002510328A (en) * 1997-07-25 2002-04-02 スミスクライン・ビーチャム・コーポレイション Vitronectin receptor antagonist
HUP0003949A2 (en) * 1997-09-24 2001-10-28 Smithkline Beecham Corp. Vitronectin receptor antagonist and pharmaceutical composition containing the compounds

Also Published As

Publication number Publication date
JP2004510708A (en) 2004-04-08
CZ2003459A3 (en) 2003-09-17
PL365729A1 (en) 2005-01-10
CN1471512A (en) 2004-01-28
NO20030925D0 (en) 2003-02-27
EA200300226A1 (en) 2003-10-30
AU2001288515A1 (en) 2002-03-13
IL154496A0 (en) 2003-09-17
MXPA03001759A (en) 2004-11-01
NZ524159A (en) 2004-08-27
CA2419699A1 (en) 2002-03-07
NO20030925L (en) 2003-04-24
EP1313705A1 (en) 2003-05-28
WO2002018340A1 (en) 2002-03-07
ZA200301162B (en) 2004-05-12
KR20030027106A (en) 2003-04-03

Similar Documents

Publication Publication Date Title
DK0894084T3 (en) Cinnamic acid derivatives and their use as integrin antagonists
ATE203515T1 (en) META-SUBSTITUTED PHENYLSULPHONAMIDE DERIVATIVES
DK0889877T3 (en) Meta-substituted phenylene derivatives and their use as alpha-beta3 integrin antagonists or inhibitors
ATE202337T1 (en) CYCLOPROPYLALKANIC ACID DERIVATIVES
ATE212978T1 (en) PARA-SUBSTITUTED PHENYLPROPANE ACID DERIVATIVES AS INTEGRIN ANTAGONISTS
MX9801716A (en) Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists.
BR9910119A (en) Heterocyclic derivatives of glycyl beta-alanine as vitronectin antagonists
GB0206860D0 (en) Compounds
BR0317600A (en) heteroarylalkanoic acids as derivatives of integrin receptor antagonists
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
TR200400238T4 (en) Alpha crystalline form of the perindopril tert-butylamine salt
TR200101961T2 (en) 1,2-ring quinoline derivatives
SE0302760D0 (en) New compounds
BR0317487A (en) The r-isomer of beta amino acid compounds as derivatives of integrin receptor antagonists
NO20040589L (en) Arylsulfonyl derivatives with 5-HT6 receptor affinity.
NZ516506A (en) Interleukin-5 inhibiting 6-azauracil derivatives
BR0113671A (en) Gem-substituted alpha v beta 3 integrin antagonists
BR0207102A (en) Crystalline form, pharmaceutical composition, use of a crystalline form, and method for the prevention or treatment of disease.
HUP0302255A2 (en) Sulfonamide derivatives, pharmaceutical compositions containing them and their use
MXPA05006587A (en) Thiazole compounds as integrin receptor antagonists derivatives.
BR0308201A (en) Quinoline derivatives
BR0317363A (en) Npy-5 antagonist
RS20050426A (en) Substituted aralkyl derivatives
GB2392095A (en) Therapeutic compositions for modulating the immune response in a mammal and use thereof
BR9915898A (en) Compounds, pharmaceutical composition, and use of a compound

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2021 DE 29/09/2009.